3.0.0 3573 2022-11-01T13:50:48Z 2022-11-01T13:50:48Z House HR 2019-06-27 116 [Congressional Record Volume 165, Number 109 (Thursday, June 27, 2019)][House][Pages H5259-H5260]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. LUJAN:H.R. 3573.[[Page H5260]]Congress has the power to enact this legislation pursuantto the following:Article 1. Section 8.]]> hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2019-06-28T19:36:27Z Referred to 2019-06-27T13:03:40Z 116 2010 S 2019-06-27 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Identical bill CRS 2019-06-28 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2019-06-27 Referred to the House Committee on Energy and Commerce. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2019-06-27 Introduced in House IntroReferral Intro-H 9 Library of Congress 2019-06-27 Introduced in House IntroReferral 1000 9 Library of Congress L000570 Rep. Lujan, Ben Ray [D-NM-3] Ben Lujan D NM R. 3 N H001080 Rep. Haaland, Debra A. [D-NM-1] Debra Haaland D NM A. 1 2019-06-27 True T000484 Rep. Torres Small, Xochitl [D-NM-2] Xochitl Torres Small D NM 2 2019-06-27 True Health Cardiovascular and respiratory health Drug safety, medical device, and laboratory regulation Drug therapy Health care quality Health facilities and institutions Health information and medical records Health promotion and preventive care Medical research Neurological disorders Research administration and funding Health

00 2019-06-27 Introduced in House 2019-07-24T18:57:24Z Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2019 or the CCM-CARE Act

This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.)

The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients.

The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation.

The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways.

]]>

Display Title Official Title as Introduced Introduced in House IH Short Title(s) as Introduced Introduced in House IH Short Title(s) as Introduced Introduced in House IH Introduced in House 2019-06-27T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr3573ih/xml/BILLS-116hr3573ih.xml 2019-06-28 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.